Last reviewed · How we verify
Enalapril Orodispersible Minitablet
Enalapril Orodispersible Minitablet is a ACE inhibitor Small molecule drug developed by Ethicare GmbH. It is currently in Phase 2 development for Hypertension, Heart failure. Also known as: Enalapril ODMT.
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing the production of angiotensin II and aldosterone, leading to vasodilation and decreased blood pressure.
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing the production of angiotensin II and aldosterone, leading to vasodilation and decreased blood pressure. Used for Hypertension, Heart failure.
At a glance
| Generic name | Enalapril Orodispersible Minitablet |
|---|---|
| Also known as | Enalapril ODMT |
| Sponsor | Ethicare GmbH |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting ACE, enalapril prevents the conversion of angiotensin I to the vasoconstrictor angiotensin II, which results in reduced systemic vascular resistance and lower blood pressure. It also reduces aldosterone secretion, decreasing sodium and water retention.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Hyperkalemia
Key clinical trials
- Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril (PHASE2, PHASE3)
- Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease (PHASE2, PHASE3)
- Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enalapril Orodispersible Minitablet CI brief — competitive landscape report
- Enalapril Orodispersible Minitablet updates RSS · CI watch RSS
- Ethicare GmbH portfolio CI
Frequently asked questions about Enalapril Orodispersible Minitablet
What is Enalapril Orodispersible Minitablet?
How does Enalapril Orodispersible Minitablet work?
What is Enalapril Orodispersible Minitablet used for?
Who makes Enalapril Orodispersible Minitablet?
Is Enalapril Orodispersible Minitablet also known as anything else?
What drug class is Enalapril Orodispersible Minitablet in?
What development phase is Enalapril Orodispersible Minitablet in?
What are the side effects of Enalapril Orodispersible Minitablet?
What does Enalapril Orodispersible Minitablet target?
Related
- Drug class: All ACE inhibitor drugs
- Target: All drugs targeting ACE
- Manufacturer: Ethicare GmbH — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
- Also known as: Enalapril ODMT
- Compare: Enalapril Orodispersible Minitablet vs similar drugs
- Pricing: Enalapril Orodispersible Minitablet cost, discount & access